Project Grant R01CA303651
Award Date 9/10/25
Completion Date 8/31/29
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a Project Grant under CFDA 93.393 - Cancer Cause and Prevention Research to St. Jude Children's Research Hospital Inc. for the "Evaluation of Cardiovascular Health Outcomes among Survivors 2 (ECHOS-2)" study. The $772,418 grant, awarded on September 1, 2025, will test the efficacy of an eHealth-delivered intervention to improve adherence to cardiomyopathy screening among adult survivors of childhood cancer. The study aims to enroll 350...
- This Cooperative Agreement award for $703,321.00, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research federal grant program (CFDA 93.393), will support the adaptation and implementation of an evidence-based patient navigation intervention for adolescent and young adult (AYA) cancer survivors. The project aims to improve coordination of care, including surveillance for cancer recurrence, management of long-term effects, and delivery of preventive and...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- The National Cancer Institute (NCI) has awarded a Cooperative Agreement totaling $1,059,908 to St. Jude Children's Research Hospital Inc. under the Cancer Cause and Prevention Research program (CFDA 93.393). This funding supports the St. Jude Lifetime Cohort (SJLIFE) study, an unparalleled longitudinal research initiative established in 2007 to investigate health outcomes and premature mortality among over 10,000 survivors of childhood and adolescent cancer. Key products and services provided...
- This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $185,693 to the Research Institute at Nationwide Children's Hospital to implement a digital health parent coaching intervention aimed at improving neurodevelopmental outcomes for young childhood cancer survivors in underserved communities. The project will be conducted over a 5-year period from March 1, 2025 to February 28, 2030. The Research Institute, a non-profit research...
- This federal Project Grant award of $676,550 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to understand the impact of socioeconomic status (SES) and adversity on hematopoietic cell transplant (HCT) outcomes in pediatric patients with high-risk hematological malignancies. The primary goals are to: 1) quantify the association between donor and recipient SES with pediatric HCT outcomes, and 2) evaluate how donor and recipient SES...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $734,942 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The project, titled "Aging, DNA Methylation, and Incident Cardiovascular Disease in Breast Cancer Survivors," aims to generate new blood DNA methylation data and conduct research to better...
- The National Cancer Institute (NCI), under the Cancer Biology Research federal grant program (CFDA 93.396), awarded a $530,106 Project Grant to the Children's Hospital Medical Center in Cincinnati, Ohio. The grant, awarded on September 11, 2025, supports research aimed at understanding and targeting polyamine metabolism in leukemia stem cells (LSCs) to improve outcomes for patients with acute myeloid leukemia (AML). The overarching goal is to develop LSC-directed therapies that can help overcome...
- The National Cancer Institute (NCI), part of the U.S. Department of Health and Human Services, awarded a $1,338,648 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the University of Pittsburgh. The grant will fund a "Hybrid Type I Cluster Randomized Effectiveness-Implementation Trial of CARES" to address clinically significant levels of depression, pain, and fatigue experienced by over 18 million Americans living with cancer. The project aims to...